NCT07369739

Golidocitinib Combined With Selinexor for CAEBVD

Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.

Conditions

• Lymphohistiocytosis
• EBV
• CAEBV

Interventions

Type	Name	Description
DRUG	golidocitinib	golidocitinib 150 mg once daily.
DRUG	Selinexor (combination therapy)	selinexor 40 mg once weekly.

Timeline

• Start date: 2026-01-01
• Primary completion: 2027-01-01
• Completion: 2028-01-01
• First posted: 2026-01-27
• Last updated: 2026-01-27

Locations

1 site across 1 country: China